Actym Therapeutics, Inc.
United States
- Berkeley, CA
- 20/10/2023
- Series A
- $59,500,000
Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies.
- Industry Biotechnology Research
- Website https://actymthera.com/
- LinkedIn https://www.linkedin.com/company/actym-therapeutics-inc/about/
Related People
Christopher ThanosCo Founder
United States -
Belvedere Tiburon, California
• Significant entrepreneurial and leadership experience in the biotechnology industry
• 30 years R&D experience
• Design, engineering, and production of cell therapies, ADC's, enzymes, and alternative scaffolds
• Comprehensive understanding of pipeline flow, from lead optimization to IND, to clinical POC
• Established skills in competitive intelligence, strategy, due diligence, portfolio management
• Inventor on multiple issued patents covering biotherapeutics
• First author publications in high impact factor journals such as Science, PNAS, JACS
• Effectively managed large teams
• Invited speaker, workshop leader, conference chair at several international meetings
Brevo | $582,532,500 | (Dec 5, 2025)
Lumia Security | $18,000,000 | (Dec 5, 2025)
imper.ai | $28,000,000 | (Dec 5, 2025)
IMTC | $12,000,000 | (Dec 5, 2025)
Govstream.ai | $3,600,000 | (Dec 5, 2025)
SPhotonix Inc | $4,500,000 | (Dec 5, 2025)
Unlimited Industries | $12,000,000 | (Dec 5, 2025)
Paradigm Health | $78,000,000 | (Dec 5, 2025)
Guide Labs | $9,000,000 | (Dec 5, 2025)
7AI | $130,000,000 | (Dec 5, 2025)
Ply | $8,500,000 | (Dec 5, 2025)
Find Your Grind | $5,000,000 | (Dec 5, 2025)